07:06:53 EDT Sun 21 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:GTHX - G1 THERAPEUTICS IN - http://www.g1therapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GTHX - Q0.53.50·3.710.43.63-0.01-0.3986.33,2584,9683.60  3.73  3.5056.14  1.0819:37:51Jul 0115 min RT 2¢

Recent Trades - Last 10 of 4968
Time ETExPriceChangeVolume
19:37:51Q3.63-0.0140
16:22:20Q3.60-0.042,755
16:02:20Q3.63-0.01993
16:02:15Q3.63-0.01576
16:01:37Q3.63-0.01520
16:00:06Q3.63-0.01288
16:00:06Q3.63-0.013
16:00:06Q3.63-0.01412
16:00:01Q3.63-0.0114
16:00:01Q3.63-0.01285

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-01 08:01U:GTHXNews ReleaseG1 Therapeutics Added to the Russell 2000(TM) and 3000(TM) Indexes
2024-06-24 06:31U:GTHXNews ReleaseG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
2024-06-05 07:01U:GTHXNews ReleaseG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-28 06:31U:GTHXNews ReleaseMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
2024-05-23 17:07U:GTHXNews ReleaseG1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
2024-05-22 10:00U:GTHXNews ReleaseG1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit
2024-05-22 06:30U:GTHXNews ReleaseG1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
2024-05-01 17:51U:GTHXNews ReleaseG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-01 06:30U:GTHXNews ReleaseG1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
2024-05-01 06:26U:GTHXNews ReleaseG1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
2024-04-17 09:01U:GTHXNews ReleaseG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
2024-04-04 10:31U:GTHXNews ReleaseG1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-04-01 16:20U:GTHXNews ReleaseG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-01 16:21U:GTHXNews ReleaseG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-28 06:31U:GTHXNews ReleaseG1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2024-02-27 08:30U:GTHXNews ReleaseG1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
2024-02-15 08:30U:GTHXNews ReleaseG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business ‚  Update on February 28, 2024
2024-02-12 16:05U:GTHXNews ReleaseG1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
2024-01-08 06:46U:GTHXNews ReleaseG1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 09:00U:GTHXNews ReleaseG1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference